Simultaneous Presentation of Ankylosing Spondylitis and Pancreatic Cancer: A Case Report

CASE REPORT
Ekaterina V. Kapustina, Gennady P. Bulygin, Vasily S. Mordovsky, Tatyana V. Potupchik, Svetlana Yu. Nikulina, Anna A. Chernova, Denis A. Medvedev, Andrey M. Budarev, Vera A. Chupakhina, Tatyana Yu. Bolshakova, Elena P. Kluchnikova

 
International Journal of Biomedicine. 2019;9(1):69-71.
DOI: 10.21103/Article9(1)_CR2
Originally published March 15, 2019

Abstract: 

A clinical case of simultaneous presentation of ankylosing spondylitis and pancreatic cancer is described. Patients with rheumatic disorders must be closely followed to screen for malignancies. Most paraneoplastic rheumatic syndromes are difficult to distinguish from autoimmune rheumatic diseases; thus, cancer occurrence may constitute a major diagnostic challenge.

Keywords: 
ankylosing spondylitis • pancreatic cancer • paraneoplastic rheumatic syndromes
References: 
  1. Wen J, Ouyang H, Yang R, Bo L, Zhang Y, Tang M, Liu Z.Malignancy dominated with rheumatic manifestations: A retrospective single-center analysis. Sci Rep. 2018;8(1):1786. doi: 10.1038/s41598-018-20167-w.
  2. Bellan M, Boggio E, Sola D, Gibbin A, Gualerzi A, Favretto S,  et al. Association between rheumatic diseases and cancer: results from a clinical practice cohort study. Intern Emerg Med. 2017;12(5):621-627. doi: 10.1007/s11739-017-1626-8.
  3. Manger B, Schett G. Rheumatic paraneoplastic syndromes - A clinical link between malignancy and autoimmunity. Clin Immunol. 2018;186:67-70. doi: 10.1016/j.clim.2017.07.021.
  4. Turesson C, Matteson EL. Malignancy as a comorbidity in rheumatic diseases. Rheumatology (Oxford). 2013;52(1):5-14. doi: 10.1093/rheumatology/kes189.
  5. Bojinca V, Janta I. Rheumatic diseases and malignancies. Maedica (Buchar). 2012;7(4):364-71.
  6. Azar L, Khasnis A. Paraneoplastic rheumatologic syndromes. Curr Opin Rheumatol. 2013;25(1):44-9. doi: 10.1097/BOR.0b013e328359e780.
  7. Naschitz JE. Rheumatic syndromes: clues to occult neoplasia.Curr Opin Rheumatol. 2001 Jan;13(1):62-6
  8. Szekanecz E, András C, Sándor Z, Antal-Szalmás P, Szántó J, Tamási L, et al. Malignancies and soluble tumor antigens in rheumatic diseases. Autoimmun Rev. 2006;6(1):42-7.
  9. Szekanecz Z, Szekanecz E, Bakó G, Shoenfeld Y. Malignancies in autoimmune rheumatic diseases - a mini-review. Gerontology. 2011;57(1):3-10. doi: 10.1159/000314634.
  10. Mantovani A, Allavena P, Sica A, Balkwill F.Cancer-related inflammation. Nature. 2008;454(7203):436-44. doi: 10.1038/nature07205.
  11. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539-45.
  12. Hreggvidsdottir HS, Noordenbos T, Baeten DL. Inflammatory pathways in spondyloarthritis. Mol Immunol. 2014;57(1):28-37. doi: 10.1016/j.molimm.2013.07.016.
  13. Chang CC, Chang CW, Nguyen PA, Chang TH, Shih YL, Chang WY, et al. Ankylosing spondylitis and the risk of cancer. Oncol Lett. 2017;14(2):1315-1322. doi: 10.3892/ol.2017.6368.
  14. Feltelius N, Ekbom A, Blomqvist P. Cancer incidence among patients with ankylosing spondylitis in Sweden 1965-95: a population based cohort study. Ann Rheum Dis. 2003;62(12):1185-8.
  15. Hemminki K, Liu X, Försti A, Ji J, Sundquist J, Sundquist K. Effect of autoimmune diseases on incidence and survival in subsequent multiple myeloma. J Hematol Oncol. 2012;5:59. doi: 10.1186/1756-8722-5-59.
  16. Hemminki K1, Liu X, Ji J, Sundquist J, Sundquist K. Autoimmune disease and subsequent digestive tract cancer by histology. Ann Oncol. 2012;23(4):927-33. doi: 10.1093/annonc/mdr333.
  17. Fallah M, Liu X, Ji J, Försti A, Sundquist K, Hemminki K. Autoimmune diseases associated with non-Hodgkin lymphoma: a nationwide cohort study. Ann Oncol. 2014;25(10):2025-30. doi: 10.1093/annonc/mdu365.
  18. Hemminki K, Liu X, Ji J, Försti A, Sundquist J, Sundquist K. Effect of autoimmune diseases on risk and survival in female cancers. Gynecol Oncol. 2012;127(1):180-5. doi: 10.1016/j.ygyno.2012.07.100.

Download Article
Received December 15, 2018.
Accepted January 16, 2019.
©2019 International Medical Research and Development Corporation.